All articles by Frankie Fattorini

Frankie Fattorini

Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.

Disruption due for long-held assumptions in biopharma, says BIA chair

Foundational certainties of the biopharma industry may no longer hold true for the sector’s future as paradigm shifts reshape the…
NewCo licensing models are tipping deals in favour of China’s biotechs

As pharma companies continue to license candidates developed in China, experts say a particular licensing model is allowing the country's…
VPAG stalemate threatens to exclude innovative medicines from the UK

Stalled negotiations around the UK's Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) between the UK government and…
Targeting energy expenditure: the next wave of obesity drugs

In the wake of their seismic ascension over the lucrative weight loss market, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are facing…
EU’s Pharma Package falls short of Europe’s goal of global competitiveness

In a bid to chase competitiveness, the EU is advancing its most drastic revision of pharmaceutical law in 20 years.…

ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study

Johnson & Johnson (J&J) has unveiled first-in-human data on its trispecific antibody that demonstrates a 100% response rate in a…
ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA

A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the…
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are…
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups

Updated analysis showed Carvykti (ciltacabtagene autoleucel) improved survival for multiple myeloma patients regardless of their cytogenetic risk or prior lines…
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC

Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of…